50 mg vs 100 mg duration is a PK→PD construct describing how different modeled dose levels modify concentration-time geometry and therefore the modeled duration window. Here, dose is strictly a modeling parameter, not a clinical instruction or real-world dose–effect statement. A modeled 100 mg trajectory can produce greater peak height, a steeper rising-phase slope, and deeper distribution loading than a modeled 50 mg trajectory when other parameters are held constant. Yet duration is determined by the geometry of the decline phase, redistribution timing, and the location of PD thresholds relative to the concentration trajectory, rather than by peak height alone. A higher modeled trajectory can therefore lengthen, compress, or leave the modeled duration interval unchanged depending on elimination, metabolic turnover, binding sensitivity, and coupling geometry. The key distinction is between scaling concentration magnitude and determining threshold-crossing persistence. This page treats sildenafil duration entirely as modeled PK→PD geometry. Link to duration basics.
Dose-dependent PK geometry begins with systemic input and propagates through peak formation, distribution loading, metabolic turnover, and elimination. Under a modeled 100 mg parameter, greater input can raise peak height and increase the amount represented in distribution compartments, potentially producing a broader or more persistent decline phase. However, the relationship is not required to be proportional. If metabolic turnover or elimination is represented as concentration-dependent, the higher trajectory can also acquire a steeper descending slope and reduce persistence. A modeled 50 mg parameter produces lower peak height and shallower distribution loading, but its duration can remain similar when the normalized decline geometry is comparable. Redistribution timing is another determinant: deeper compartment loading can delay return flow into the central compartment, whereas shallower loading can make redistribution earlier and less prolonged. Consequently, dose changes alter multiple PK coordinates simultaneously rather than defining duration by magnitude alone. Link to distribution differences and metabolism differences.
PD interpretation converts the modeled concentration trajectory into a threshold and response-coordinate geometry. Threshold placement determines where the rising and falling concentration paths intersect the modeled PD boundary, so a higher 100 mg trajectory may cross earlier and remain above the boundary longer, while another threshold placement can reduce or erase that duration separation. Binding sensitivity controls how concentration differences are transformed into a binding coordinate: greater sensitivity expands separation between dose trajectories, whereas lower sensitivity compresses it. Coupling geometry then maps binding into downstream PD coordinates, with steep coupling slopes potentially moving threshold crossings closer together and shallow slopes potentially spreading them apart. PD noise bands add transition width around the nominal boundary, making modeled entry and exit less sharply defined. Thus, identical 50 mg versus 100 mg PK scaling can yield different duration intervals under different PD mappings, while different PK trajectories can converge when threshold and coupling parameters compensate. Link to peak vs duration.
In the modeled PK layer, changing the parameter from 50 mg to 100 mg scales systemic input and can alter several linked coordinates of the concentration-time curve. Peak height generally rises when the modeled input amount is doubled while absorption and disposition parameters remain fixed, and the rising-phase slope can become steeper because the trajectory reaches higher concentrations over a similar input interval. Greater concentration exposure also represents deeper distribution loading when compartmental partitioning is included. That deeper loading can change the timing and magnitude of redistribution back toward the central compartment during the descending phase. These changes affect duration only through their influence on persistence relative to the modeled PD boundary. A higher peak can provide more concentration remaining after the peak, but it does not independently specify the exit time. Absorption timing, distribution structure, and return flow must therefore be interpreted together when comparing the two modeled dose parameters. This is the core dose-geometry layer. Link to absorption duration.
Metabolic turnover and elimination determine how the dose-scaled trajectory contracts after peak formation. In a simple linear model, increasing the modeled input from 50 mg to 100 mg can raise concentrations while preserving the same fractional elimination slope, causing the absolute concentration trajectory to remain separated for part of the decline. Duration then depends on where each trajectory intersects the selected PD threshold. In a nonlinear model, however, higher concentrations can be assigned altered metabolic or elimination rates, changing the descending slope itself. A 100 mg parameter may therefore show greater persistence, similar persistence, or reduced persistence relative to the 50 mg parameter depending on the specified turnover function. Distribution can further modify the apparent terminal phase by returning drug from peripheral compartments while elimination continues. The resulting duration geometry is consequently a composite of metabolic clearance, elimination rate, compartmental redistribution, and threshold position rather than a direct consequence of nominal dose magnitude. The model equations define the comparison. Link to metabolism duration.
| PK Domain | 50 mg Effect | 100 mg Effect | Link |
|---|---|---|---|
| Peak Height | Moderate modeled peak. | Higher modeled peak. | peak vs duration |
| Distribution Loading | Moderate modeled loading. | Deeper modeled loading. | distribution duration |
| Elimination | Lower modeled trajectory. | Higher modeled trajectory with parameter-dependent decline. | half-life duration |
Threshold placement determines how a dose-scaled PK trajectory becomes a modeled duration interval. If the PD threshold is positioned near the lower part of the concentration trajectory, both 50 mg and 100 mg paths may remain above it for a longer modeled interval, with the higher trajectory potentially crossing the threshold later during decline. If the threshold is placed higher, the same trajectories can exit sooner, and the difference between them may either expand or contract depending on curve shape. The rising phase also matters because threshold entry contributes to the beginning of the modeled window, not only its exit. A higher modeled 100 mg trajectory can cross an entry threshold earlier when its peak and rising slope are greater. Yet threshold placement can be adjusted independently of dose, so no fixed duration follows from the 50 mg or 100 mg parameter itself. Duration is the interval produced by intersections between the PK path and the selected PD boundaries. Link to onset–duration interaction.
Binding sensitivity and coupling geometry determine how concentration separation between modeled 50 mg and 100 mg trajectories is transformed into PD-coordinate separation. With higher binding sensitivity, a given concentration difference can create a larger separation in the modeled binding coordinate, potentially shifting threshold crossings farther apart. With lower sensitivity, concentration differences can be compressed, making duration intervals more similar even when peak heights differ substantially. Coupling geometry adds another transformation: a steep concentration-to-PD slope can magnify local changes around a threshold, while a shallow slope can distribute those changes over a broader concentration range. PD noise bands introduce an additional transition region around the nominal threshold, so modeled entry and exit become bands rather than perfectly sharp points. These mechanisms mean that dose-dependent persistence is not read directly from concentration. The final duration interval depends on the combined mapping from concentration to binding, from binding to PD coordinates, and from those coordinates to the selected threshold and noise boundaries. Link to duration stability.
| PD Domain | 50 mg Interaction | 100 mg Interaction | Link |
|---|---|---|---|
| Threshold Placement | Threshold crossing depends on boundary position. | Threshold crossing may shift later or earlier. | peak vs duration |
| Binding Sensitivity | Potentially compressed mapping. | Potentially amplified mapping. | duration stability |
| Coupling Geometry | Modeled slope determines separation. | Slope can expand or compress separation. | duration predictability |
A cross-compound PK comparison can be represented without assigning clinical meaning to either dose parameter. In a sildenafil model, the dose-to-duration relationship depends on how the selected 50 mg and 100 mg input parameters propagate through absorption, distribution, metabolism, and elimination. A model with relatively rapid terminal decline can show a compact duration window even when the higher parameter produces a taller peak. The higher trajectory may still cross a lower PD threshold later because more concentration remains during decline, but the extension is controlled by the elimination slope and distribution return flow. A compound represented with slower modeled elimination would retain concentration longer, making duration geometry less dominated by short-term peak differences. The comparison therefore concerns parameterized PK shape, not real-world duration or therapeutic performance. Across compounds, dose scaling, clearance, redistribution, and PD threshold placement can produce different interval geometries even when input parameters are numerically identical. The model structure determines persistence. Link to duration comparison overview.
For a second compound represented with slower modeled elimination and extended redistribution, increasing a dose parameter can produce a smaller change in normalized decline slope than in a model with faster turnover. That can make separation between lower and higher dose trajectories persist across a broader modeled time axis. This is a mathematical comparison of PK parameterizations rather than a statement about real-world duration. The same principle applies to sildenafil when clearance and compartment parameters are altered within a model: the duration interval emerges from concentration persistence and PD thresholds. A longer modeled terminal component can preserve concentration near a threshold after peak differences have diminished, while a shorter terminal component can move both trajectories rapidly below the boundary. Distribution can reinforce or counteract this behavior through delayed return flow. Thus, cross-compound dose–duration geometry should be interpreted through elimination and redistribution parameters, not a universal dose-to-duration rule. Link to duration curve comparison.
PK→PD mapping can amplify or compress the duration difference between modeled 50 mg and 100 mg trajectories after their PK paths have been generated. A low threshold near the declining tail can preserve separation because the higher trajectory reaches that boundary later. A higher threshold can place both crossings closer to their peaks, reducing the contribution of the terminal tail. Binding sensitivity can magnify concentration separation, while a compressive binding relationship can make the two trajectories nearly overlap in the PD coordinate. Coupling slopes determine how binding differences propagate into the final PD signal, and noise bands broaden threshold interpretation. Identical PK scaling can therefore generate different duration intervals under different PD parameter sets. Conversely, different concentration curves can generate similar intervals when threshold placement and coupling geometry compensate for differences in peak height, redistribution, or elimination. Dose enters duration indirectly through a sequence of modeled transformations rather than as a direct duration multiplier. Link to pkpd duration.
| Compound | Dose Behavior | Duration Behavior | Link |
|---|---|---|---|
| Sildenafil | Modeled dose scaling changes trajectory magnitude and shape. | Duration depends on modeled decline and threshold geometry. | why sildenafil wears off |
| Tadalafil | Modeled dose scaling interacts with slower modeled disposition parameters. | Duration depends on modeled persistence and redistribution. | duration comparison overview |
| Mapping | Amplifies or compresses PK differences. | Threshold geometry determines mapped persistence. | pkpd duration |
When 50 mg and 100 mg are treated as PK modeling parameters, the higher parameter changes the concentration-time trajectory rather than directly assigning a duration. Holding other parameters constant can raise peak height, steepen the rising phase, and increase distribution loading. The modeled duration interval is then determined by how the declining trajectory intersects selected PD thresholds. Linear elimination may preserve a similar fractional decline slope, while nonlinear turnover can alter decline shape at higher concentrations. Threshold placement, binding sensitivity, coupling geometry, and PD noise bands can amplify or compress the resulting interval difference. Consequently, a modeled 100 mg trajectory can produce a longer, similar, or shorter duration interval than a modeled 50 mg trajectory depending on the parameter set. The comparison describes mathematical PK→PD geometry only and does not establish a real-world dose–duration relationship.
The main PK mechanisms are systemic input, peak formation, distribution loading, metabolic turnover, redistribution, and elimination. A modeled 100 mg parameter can generate a higher peak and steeper rising phase than a modeled 50 mg parameter when absorption characteristics are otherwise matched. Greater modeled exposure can also load peripheral compartments more deeply, changing return flow during decline. Metabolic turnover and elimination then determine how quickly the trajectory contracts. In a linear disposition model, dose scaling may preserve fractional decline geometry, while nonlinear turnover can change the decline slope at higher concentrations. These mechanisms operate together, so peak height is not equivalent to duration. The modeled interval is produced when the resulting trajectory intersects a defined PD boundary. Thus, dose-dependent duration differences reflect input, distribution, metabolism, redistribution, and elimination rather than a single dose variable or fixed duration multiplier.
PD mechanisms determine how the PK trajectory is translated into a duration interval. Threshold placement is central because moving the threshold changes entry and exit times without changing the concentration curve. Binding sensitivity controls how concentration differences between modeled 50 mg and 100 mg trajectories appear in a binding coordinate. Greater sensitivity can expand their separation, whereas lower sensitivity can compress it. Coupling geometry then maps binding into a downstream PD coordinate, with slope and curvature affecting threshold approach and exit. PD noise bands add a finite transition region around the nominal boundary, making modeled crossings less sharply defined. These layers can amplify, reduce, or redistribute the duration difference created by PK scaling. The final interval is not a direct readout of concentration or nominal dose; it results from a specified concentration-to-binding-to-PD mapping combined with explicit threshold and uncertainty-band parameters.
Steep dose–duration scaling is not an inherent rule; it can arise in a model when dose scaling changes the relationship between concentration persistence and the selected PD threshold. A higher modeled input may raise the peak, increase distribution loading, and leave a greater concentration margin above a threshold during decline. If elimination is rapid, however, that extra margin can disappear quickly, limiting duration separation. Nonlinear turnover can also change the decline slope. Threshold placement matters: a threshold near the terminal tail makes persistence differences more influential, while a threshold closer to the peak makes early geometry more influential. Binding sensitivity, coupling slopes, and noise bands further modify the mapped interval. Thus, steepness in a modeled dose–duration curve reflects the combined PK and PD parameterization, not a universal real-world dose–duration law.
PK→PD mapping explains dose–duration differences by converting concentration geometry into threshold-crossing geometry. A dose parameter establishes the scale and shape of systemic input, affecting peak height, rising-phase slope, and distribution loading. Metabolism, redistribution, and elimination determine the descending trajectory. The PD layer then transforms concentration through binding sensitivity and coupling geometry before applying threshold placement and noise bands. A higher modeled 100 mg trajectory can remain separated from a modeled 50 mg trajectory in concentration space but become less separated after a compressive PD transformation. The reverse can occur when binding sensitivity or coupling slopes amplify differences around the threshold. Because entry and exit are defined by intersections with mapped PD boundaries, duration depends on the whole transformation chain. The modeled interval is an emergent property of specified PK equations and PD mapping parameters, not a real-world dose–effect claim.